Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-α

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 285, Issue 5 29-5, 2003, Pages

  Le Cras, Timothy D ^a   Hardie, William D ^a   Fagan, Karen ^b   Whitsett, Jeffrey A ^a   Korfhagen, Thomas R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis; Bronchopulmonary dysplasia; Epidermal growth factor receptor; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOGRAPHY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; LUNG BLOOD VESSEL; LUNG DYSPLASIA; MORBIDITY; MORTALITY; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; TRANSGENIC MOUSE; VASCULARIZATION;

EID: 0142244100     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00045.2003     Document Type: Article

References (41)

1. Abman SH and Sondheimer HM. Pulmonary circulation and cardiovascular sequelae of BPD. In: Diagnosis and Treatment of Pulmonary Hypertension, edited by Weir EK, Archer SL, and Reeve JT. Mount Kisco, NY: Futura, 1992, p. 155-180.
2. Baughman RP, Lower EE, Miller MA, Bejarano PA, and Heffelfinger SC. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 16: 57-61, 1999.
3. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, and Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164: 1971-1980, 2001.
4. Bland R and Coalson JJ. Chronic Lung Disease in Early Infancy. New York: Dekker, 2000.
5. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996.
6. Chesnutt AN, Kheradmand F, Folkesson HG, Alberts M, and Matthay MA. Soluble transforming growth factor-alpha is present in the pulmonary edema fluid of patients with acute lung injury. Chest 111: 652-656, 1997.
7. Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, and Yoder BA. Lung injury in neonates: causes, strategies for prevention, and long-term consequences. J Pediatr 139: 478-486, 2001.
8. DeMello D, Sawyer D, Galvin N, and Reid LM. Early fetal development of lung vasculature. Am J Respir Cell Mol Biol 16: 568-581, 1997.
9. Derynck R. Transforming growth factor-α. Cell 54: 593-595, 1988.
10. Derynck R, Roberts AB, Winkler ME, Chen EY, and Goeddel DV. Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell 38: 287-297, 1984.
11. Fagan K, Fouty BW, Tyler RC, Morris KG, Hepler LK, Sato K, Le Cras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, and Rodman DM. The pulmonary circulation of mice with either homozygous or heterozygous dysruption of the endothelial nitric oxide synthase is hyper-responsive to chronic hypoxia. J Clin Invest 103: 291-299, 1999.
12. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996.
13. Gebb SA and Shannon JM. Tissue interactions mediate early events in pulmonary vasculogenesis. Dev Dyn 217: 159-169, 2000.
14. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, and Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126: 1149-1159, 1999.
15. Greenberg JM, Thompson FY, Brooks SK, Shannon JM, McCormick-Shannon K, Cameron JE, Mallory BP, and Akeson AL. Mesenchymal expression of vascular endothelial growth factors D and A defines vascular patterning in developing lung. Dev Dyn 224: 144-153, 2002.
16. Hardie WD, Bejarano PA, Miller MA, Yankaskas JR, Ritter JH, Whitsett JA, and Korfhagen TR. Immunolocalization of transforming growth factor alpha and epidermal growth factor receptor in lungs of patients with cystic fibrosis. Pediatr Dev Pathol 2: 415-423, 1999.
17. Hardie WD, Bruno MD, Huelsman KM, Iwamoto HS, Carrigan PE, Leikauf GD, Whitsett JA, and Korfhagen TR. Postnatal lung function and morphology in transgenic mice expressing transforming growth factor-alpha. Am J Pathol 151: 1075-1083, 1997.
18. Hardie WD, Kerlakian CB, Bruno MD, Huelsman KM, Wert SE, Glasser SW, Whitsett JA, and Korfhagen TR. Reversal of lung lesions in transgenic transforming growth factor alpha mice by expression of mutant epidermal growth factor receptor. Am J Respir Cell Mol Biol 15: 499-508, 1996.
19. Hardie WD, Piljan-Gentle A, Dunlavy MR, Ikegami M, and Korfhagen TR. Dose-dependent lung remodeling in transgenic mice expressing transforming growth factor-α. Am J Physiol Lung Cell Mol Physiol 281: L1088-L1094, 2001.
20. Healy AM, Morgenthau L, Zhu X, Farber HW, and Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn 219: 341-352, 2000.
21. Huang YC, Wu W, Ghio AJ, Carter JD, Silbajoris R, Devlin R, and Samet JM. Activation of EGF receptors mediates pulmonary vasoconstriction induced by residual oil fly ash. Exp Lung Res 28: 19-38, 2002.
22. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, and Abman SH. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279: L600-L607, 2000.
23. Jobe AH and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723-1729, 2001.
24. Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, and Whitsett JA. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest 93: 1691-1699, 1994.
25. Kubiak J, Mitra MM, Steve AR, Hunt JD, Davies P, and Pitt BR. Transforming growth factor-alpha gene expression in late-gestation fetal rat lung. Pediatr Res 31: 286-290, 1992.
26. Lassus P, Ristimaki A, Ylikorkala O, Viinikka L, and Andersson S. Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med 159: 1429-1433, 1999.
27. Lassus P, Turanlahti M, Heikkila P, Andersson LC, Nupponen I, Sarnesto A, and Andersson S. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 164: 1981-1987, 2001.
28. Le Cras TD, Markham N, Tuder R, Voelkel NF, and Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283: L555-L562, 2002.
29. Lordan JL, Bucchieri Richter A, Konstantinidis A, Holloway JW, Thornber M, Puddicombe SM, Buchanan D, Wilson SJ, Djukanovic R, Holgate ST, and Davies DE. Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol 169: 407-414, 2002.
30. Madtes DK, Busby HK, Strandjord TP, and Clark JG. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 11: 540-551, 1994.
31. Madtes DK, Elston AL, Hackman RC, Dunn AR, and Clark JG. Transforming growth factor-alpha deficiency reduces pulmonary fibrosis in transgenic mice. Am J Respir Cell Mol Biol 20: 924-934, 1999.
32. Madtes DK, Rubenfeld G, Klima LD, Milberg JA, Steinberg KP, Martin TR, Raghu G, Hudson LD, and Clark JG. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 158: 424-430, 1998.
33. Pardanaud L and Dieterlen-Lievre F. Manipulation of the angiopoietic/hemangiopoietic commitment in the avian embryo. Development 126: 617-627, 1999.
34. Schreiber AB, Winkler ME, and Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232: 1250-1253, 1986.
35. Shannon JM and Deterding RR. Epithelial-mesenchymal interactions in lung development. In: Lung Growth and Development, edited by McDonald JA. New York: Dekker, 1997, p. 81-118.
36. Stahlman MT, Orth DN, and Gray ME. Localization of epidermal growth factor in the developing human respiratory system and in acute and chronic lung disease in the neonate. Lab Invest 60: 539-547, 1989.
37. Strandjord TP, Clark JG, Guralnick DE, and Madtes DK. Immunolocalization of transforming growth factor-alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung. Pediatr Res 38: 851-856, 1995.
38. Strandjord TP, Clark JG, and Madtes DK. Expression of TGF-α, EGF, and EGF receptor in fetal rat lung. Am J Physiol Lung Cell Mol Physiol 267: L384-L389, 1994.
39. Vizza CD, Lynch JP, Ochoa LL, Richardson G, and Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 113: 576-583, 1998.
40. Waheed S, D'Angio CT, Wagner CL, Madtes DK, Finkelstein JN, Paxhia A, and Ryan RM. Transforming growth factor alpha (TGF-α) is increased during hyperoxia and fibrosis. Exp Lung Res 28: 361-372, 2002.
41. Zaidi SH, You XM, Ciura S, Husain M, and Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516-521, 2002.